Zimbabwe has rejected a significant American health deal valued at $367m (272 million pounds) over five years because of Washington's request for sensitive data.
The decision came to light following a internal memorandum from December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the agreement was "lopsided".
An official spokesman has since stated that the United States was requesting biological samples for research and commercial purposes but was unwilling to share the benefits from any future medical innovations.
"We will now turn to the challenging and unfortunate task of ending our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the US had donated over $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has urged continued talks to reach a agreement agreeable to all parties so the country's critical HIV treatment initiative can continue.
Wider Background
This development follows a similar situation in Kenya, where a court halted a related deal with the US after concerns were filed about the safety of Kenyans' health data.
After resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
USAID had managed assistance for the American government, but Trump claimed its expenditure was "inefficient" and his administration was pursuing government-to-government deals to boost openness and accountability.
As per statements, 16 nations in Africa have so far agreed to similar agreements, representing over $18.3bn in new funding.
Details of the Rejected Deal
The funds for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration would have delivered immense benefits for the people of Zimbabwe, especially the 1.2 million currently receiving HIV treatment via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"Our nation was requested to share its genetic material and health information over an extended period, without any equivalent promise of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that shared data," he stated.
"Effectively, our nation would provide the basic resources for medical research without any certainty that the final treatments would be available to our people if a new pandemic emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the US's withdrawal from the global health body and its push of bilateral deals were upending structures previously set up via the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme designed to manage future global health emergencies.
"This framework is designed to ensure that when a nation contributes its samples, the benefits – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the capability to create them."
These objections over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We welcome continued dialogue with our US partners on how future co-operation could be structured in a way that respects the sovereignty and interests of both nations."
Health Experts Response
Medical experts said it understood the government's concerns, but recommended that negotiations need to persist since a large portion of the country's Aids initiatives relied on international support.
"In cases where specific concerns exist, including those involving data governance or agreement terms, these can often be addressed through detailed discussion and negotiated safeguards," it said.
The situation highlights the continuing tensions between receiving vital foreign assistance and protecting local interests in an increasingly interconnected world.